CSIMarket Company Name, Ticker, Industry, else..
 
Meiragtx Holdings Plc  (NASDAQ: MGTX)
 
Price: $13.8900 $-0.08 -0.573%
Day's High: $14.039999961853027 Week Perf: 0.58 %
Day's Low: $ 13.60 30 Day Perf: 8.6 %
Volume (M): 491,096 52 Wk High: $ 15.35
Volume (M$): $ 0 52 Wk Avg: $9.42
Open: $13.70 52 Wk Low: $6.62



 Market Capitalization (Millions $) 1,303
 Shares Outstanding (Millions) 94
 Employees 403
 Revenues (TTM) (Millions $) 398
 Net Income (TTM) (Millions $) 79
 Cash Flow (TTM) (Millions $) 43
 Capital Exp. (TTM) (Millions $) 3

Business Description


MeiraGTx Holdings Plc is a clinical-stage gene therapy company that focuses on the development of transformative treatments for various genetic diseases. The company utilizes its proprietary technology platform to create gene therapies that address the underlying causes of these diseases. MeiraGTx is dedicated to advancing the field of gene therapy through its innovative research, partnerships, and collaborations. The company has a diverse pipeline of programs targeting a range of genetic disorders, including ocular diseases, neurodegenerative disorders, and rare diseases. MeiraGTx aims to provide patients with long-term, durable treatments that can significantly improve their quality of life.


   Company Address: 655 Third Avenue, Suite 1115 New York 10017 NY
   Company Phone Number: 860-7985   Stock Exchange / Ticker: NASDAQ MGTX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ATRA        6.09% 
BEAM        1.16% 
DNA   -0.14%    
IMCR   -1.34%    
RGNX   -7.45%    
VYGR   -0.85%    
• View Complete Report
   



Clinical Study

Evolving Vision MeiraGTxs Gene Therapy Restores Sight for Children with LCA4,

Published Fri, Feb 21 2025 12:44 PM UTC

In an extraordinary breakthrough in the field of genetic medicine, MeiraGTx Holdings plc (Nasdaq: MGTX), a leading clinical-stage genetic medicines company, has announced the publication of a significant study in The Lancet that reports the efficacy of its gene therapy, rAAV8.hRKp.AIPL1, in treating children with AIPL1-associated severe retinal dystrophy, specifically Leber ...
Shares

Hope on the Horizon: Positive Data from Phase 1 AQUAx Study Brings Promising Results for Patients with Radiation-Induced Xerostomia,

Published Mon, Aug 12 2024 11:06 AM UTC

Positive Results from Phase 1 AQUAx Study Bring Hope for Patients with Radiation-Induced Xerostomia
Radiation therapy is a common treatment for head and neck cancers, but it often comes with side effects such as radiation-induced xerostomia (RIX), also known as dry mouth. This condition can significantly impact a patient s quality of life, making it difficult to speak, e...
Financing Agreement

MeiraGTx Receives $50 Million Milestone for XLRP Treatment and Improves Total Debt to Equity Ratio

Published Tue, Feb 13 2024 1:01 PM UTC


In a significant development for MeiraGTx, the company is set to receive a $50 million milestone payment after initiating the extension study for the Phase 3 LUMEOS clinical trial for botaretigene sparoparvovec (bota-vec), formerly known as AAV-RPGR, for the treatment of X-linked retinitis pigmentosa (XLRP). This milestone payment from Janssen Pharmaceuticals reflects p...
Financing Agreement

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million, Fueling Hope for X-linked Retinitis Pigmentosa Patients

Published Thu, Dec 21 2023 12:00 PM UTC

MeiraGTx Announces $415 Million Asset Purchase Agreement for X-linked Retinitis Pigmentosa Treatment
MeiraGTx Holdings Plc, a leading gene therapy company, has recently entered into an Asset Purchase Agreement related to botaretigene sparoparvovec (known as bota-vec, formerly AAV-RPGR). This agreement aims to further develop and commercialize bota-vec for the treatment o...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 19.56
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 3.28
Price to Sales (Expected) -
Price to Book 6.04
PEG (TTM) -

Financial Strength Current
Quick Ratio 2.46
Working Capital Ratio 3.17
Leverage Ratio (MRQ) 0.84
Total Debt to Equity 0.46
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) 0.71 $
Revenues (TTM) 4.24 $
Cash Flow (TTM) 0.46 $
Cash 1.53 $
Book Value 2.3 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 986,355
Net Income per Employee (TTM) 195,859
Receivable Turnover Ratio (TTM) 108.27
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 1.45

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) 76.04 %
Net Margin (MRQ) 49.99 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 28.86 %
Return On Investment (TTM) 55.83 %
Return On Equity (TTM) 283.67 %
Dividend Yield -
Pay out Ratio (TTM) -



Meiragtx Holdings Plc's Segments
Service    3.7 % of total Revenue
Related Party Service Revenue    11.79 % of total Revenue
Related Party License Revenue    63.65 % of total Revenue
Single Reportable Segment    63.67 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.